SOLUTION Group

SOLUTION Group Bhd (SGB), through its wholly-owned subsidiary Solution Biologics Sdn Bhd (SOLBIO), has signed an exclusive distribution agreement with China-based Xiamen Innovax Biotech Co Ltd (INNOVAX) to register, commercialise and distribute the Cecolin Human Papillomavirus (HPV) vaccine in Malaysia.

Under the agreement, SOLBIO will hold exclusive rights to register, import, promote and market Cecolin, a recombinant HPV bivalent vaccine targeting HPV types 16 and 18 – the primary causes of cervical cancer – for women aged 9 to 45 years.

The vaccine, produced using Escherichia coli expression technology, has a 36-month shelf life and meets World Health Organization (WHO) prequalification standards.

“This partnership with INNOVAX is a major step forward for SOLBIO in expanding our vaccine portfolio and supporting public health efforts in Malaysia,” said SGB’s group CEO Datuk Mohd Nazlee Kamal.

“Cecolin provides a cost-effective and globally recognized solution to HPV prevention, and we are proud to make it accessible to our communities,” he added.

“We believe this partnership will drive greater vaccine accessibility and cervical cancer prevention in the region,” INNOVAX GM Huirong Pan said.

The agreement follows a series of discussions between both parties aimed at strengthening healthcare outcomes through access to high-quality, affordable vaccines. — TMR